ASX - Delayed Quote AUD

Paragon Care Limited (PGC.AX)

Compare
0.5450
+0.0050
+(0.93%)
At close: 4:10:33 PM GMT+11
Loading Chart for PGC.AX
DELL
  • Previous Close 0.5400
  • Open 0.5400
  • Bid 0.5400 x --
  • Ask 0.5450 x --
  • Day's Range 0.5300 - 0.5550
  • 52 Week Range 0.2000 - 0.5900
  • Volume 565,617
  • Avg. Volume 917,018
  • Market Cap (intraday) 902.144M
  • Beta (5Y Monthly) 1.42
  • PE Ratio (TTM) 54.50
  • EPS (TTM) 0.0100
  • Earnings Date Feb 27, 2025 - Mar 3, 2025
  • Forward Dividend & Yield 0.01 (3.08%)
  • Ex-Dividend Date Sep 18, 2023
  • 1y Target Est 0.53

Paragon Care Limited supplies durable medical equipment, medical devices, and consumable medical products to health, aged care, and veterinary markets in Australia, New Zealand, and Asia. It operates through four segments: Diagnostic and Scientific, Devices, Capital and Consumables, and Service and Technology. The company offers clinical solutions for anaesthetists, intensivists, cardiac, vascular, and pain management; designs, manufactures, and distributes reagent red blood cells, monoclonal blood grouping reagents, and ancillary products for immunohaematology laboratories; and eye care products, such as ophthalmology and optometry, neonatal vision screening, and procedural kits. It also provides neonatal and paediatric assessment and treatment, including newborn hearing and vision screening, jaundice management, targeted temperature management, cerebral function monitoring, and seizure detection, as well as pain management and enteral feeding solutions; surgical products for hip and knee arthroplasty, infection prevention, pain management, biologics, and the operating room; and equipment repair and maintenance services. In addition, the company offers sterilisable transducers for neurology, hepatobiliary, renal, colorectal, vascular, laparoscopic, and robotic procedures; ultrasound systems, shockwave therapy, lasers, and accessories for infection control; and veterinary products, including point-of-care diagnostics, therapeutic lasers, oncology delivery products, centrifuges, autoclaves, IV lines and fluid therapy products, wearable CRI systems, and IT Solutions. Further, it provides digital theatre integration, telephony, nurse call, access control, CCTV, cordless, and Wi-Fi systems; and anaesthesia masks, circuits, filters, bladder scanners, and defibrillators. The company was formerly known as Citrofresh International Limited and changed its name to Paragon Care Limited in June 2008. The company was incorporated in 1994 and is based in Mt Waverley, Australia.

www.paragoncare.com.au

--

Full Time Employees

June 30

Fiscal Year Ends

Recent News: PGC.AX

View More

Performance Overview: PGC.AX

Trailing total returns as of 2/7/2025, which may include dividends or other distributions. Benchmark is

.

YTD Return

PGC.AX
13.54%
S&P/ASX 200 [XJO]
4.32%

1-Year Return

PGC.AX
147.73%
S&P/ASX 200 [XJO]
11.42%

3-Year Return

PGC.AX
58.57%
S&P/ASX 200 [XJO]
18.43%

5-Year Return

PGC.AX
115.27%
S&P/ASX 200 [XJO]
21.20%

Compare To: PGC.AX

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: PGC.AX

View More

Valuation Measures

As of 2/7/2025
  • Market Cap

    902.14M

  • Enterprise Value

    1.13B

  • Trailing P/E

    60.56

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.17

  • Price/Book (mrq)

    3.09

  • Enterprise Value/Revenue

    0.38

  • Enterprise Value/EBITDA

    26.26

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    2.64%

  • Return on Assets (ttm)

    3.12%

  • Return on Equity (ttm)

    4.74%

  • Revenue (ttm)

    317.02M

  • Net Income Avi to Common (ttm)

    10.31M

  • Diluted EPS (ttm)

    0.0100

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    28.35M

  • Total Debt/Equity (mrq)

    59.75%

  • Levered Free Cash Flow (ttm)

    1.74M

Research Analysis: PGC.AX

View More

People Also Watch